Supriya Lifescience Future Growth
Future criteria checks 5/6
Supriya Lifescience is forecast to grow earnings and revenue by 24.8% and 23.7% per annum respectively. EPS is expected to grow by 24.7% per annum. Return on equity is forecast to be 18.1% in 3 years.
Key information
24.8%
Earnings growth rate
24.74%
EPS growth rate
| Pharmaceuticals earnings growth | 16.2% |
| Revenue growth rate | 23.7% |
| Future return on equity | 18.05% |
| Analyst coverage | Low |
| Last updated | 18 Nov 2025 |
Recent future growth updates
Recent updates
Supriya Lifescience Limited's (NSE:SUPRIYA) Shareholders Might Be Looking For Exit
Jul 03
Here's Why We Think Supriya Lifescience (NSE:SUPRIYA) Might Deserve Your Attention Today
Apr 04Subdued Growth No Barrier To Supriya Lifescience Limited's (NSE:SUPRIYA) Price
Mar 04
Expansion Into High-Margin Therapeutic Segments Like Anti-Stimulants Will Strengthen Future Prospects
Expanding into high-margin therapeutic segments and increasing exports highlight Supriya Lifescience's potential for robust future revenue growth.Supriya Lifescience Limited (NSE:SUPRIYA) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Nov 07Supriya Lifescience (NSE:SUPRIYA) Has Announced That It Will Be Increasing Its Dividend To ₹0.80
Sep 08We Think You Should Be Aware Of Some Concerning Factors In Supriya Lifescience's (NSE:SUPRIYA) Earnings
Jun 05Little Excitement Around Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings
May 10Lacklustre Performance Is Driving Supriya Lifescience Limited's (NSE:SUPRIYA) Low P/E
Feb 09Supriya Lifescience's (NSE:SUPRIYA) Shareholders May Want To Dig Deeper Than Statutory Profit
May 28Market Cool On Supriya Lifescience Limited's (NSE:SUPRIYA) Earnings Pushing Shares 27% Lower
May 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2028 | 12,999 | 3,295 | N/A | 2,569 | 1 |
| 3/31/2027 | 10,314 | 2,475 | N/A | 2,002 | 1 |
| 3/31/2026 | 8,341 | 1,954 | N/A | 1,616 | 1 |
| 9/30/2025 | 7,147 | 1,824 | -7 | 1,281 | N/A |
| 6/30/2025 | 6,809 | 1,781 | N/A | N/A | N/A |
| 3/31/2025 | 6,965 | 1,880 | 23 | 1,647 | N/A |
| 12/31/2024 | 6,706 | 1,745 | N/A | N/A | N/A |
| 9/30/2024 | 6,250 | 1,575 | -189 | 1,495 | N/A |
| 6/30/2024 | 5,990 | 1,352 | N/A | N/A | N/A |
| 3/31/2024 | 5,703 | 1,191 | -323 | 1,133 | N/A |
| 12/31/2023 | 5,545 | 1,204 | N/A | N/A | N/A |
| 9/30/2023 | 5,195 | 1,001 | 72 | 1,322 | N/A |
| 6/30/2023 | 4,916 | 931 | N/A | N/A | N/A |
| 3/31/2023 | 4,609 | 899 | -443 | 636 | N/A |
| 12/31/2022 | 5,069 | 978 | N/A | N/A | N/A |
| 9/30/2022 | 5,188 | 1,280 | -191 | 226 | N/A |
| 6/30/2022 | 5,545 | 1,693 | N/A | N/A | N/A |
| 3/31/2022 | 5,300 | 1,518 | -111 | 488 | N/A |
| 12/31/2021 | 4,754 | 1,543 | N/A | N/A | N/A |
| 3/31/2021 | 3,912 | 1,236 | 276 | 759 | N/A |
| 3/31/2020 | 3,200 | 734 | 915 | 1,161 | N/A |
| 3/31/2019 | 2,818 | 394 | N/A | 487 | N/A |
| 3/31/2018 | 2,168 | 87 | N/A | 278 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SUPRIYA's forecast earnings growth (24.8% per year) is above the savings rate (6.8%).
Earnings vs Market: SUPRIYA's earnings (24.8% per year) are forecast to grow faster than the Indian market (16.6% per year).
High Growth Earnings: SUPRIYA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SUPRIYA's revenue (23.7% per year) is forecast to grow faster than the Indian market (10.9% per year).
High Growth Revenue: SUPRIYA's revenue (23.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SUPRIYA's Return on Equity is forecast to be low in 3 years time (18.1%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/27 08:00 |
| End of Day Share Price | 2025/11/27 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Supriya Lifescience Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | K.R. Choksey Shares & Securities Private Ltd. |